<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39399815</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2055-6640</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of virus eradication</Title><ISOAbbreviation>J Virus Erad</ISOAbbreviation></Journal><ArticleTitle>Indomethacin inhibits human seasonal coronaviruses at late stages of viral replication in lung cells: Impact on virus-induced COX-2 expression.</ArticleTitle><Pagination><StartPage>100387</StartPage><MedlinePgn>100387</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100387</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jve.2024.100387</ELocationID><Abstract><AbstractText>Coronaviruses (CoV), zoonotic viruses periodically emerging worldwide, represent a constant potential threat to humans. To date, seven human coronaviruses (HCoV) have been identified: HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1, globally circulating in the human population (seasonal coronaviruses, sHCoV), and three highly-pathogenic coronaviruses, SARS-CoV, MERS-CoV and SARS-CoV-2. Although sHCoV generally cause only mild respiratory diseases, severe complications may occur in specific populations, highlighting the need for broad-spectrum anti-coronavirus drugs. Herein we show that indomethacin (INDO), a non-steroidal anti-inflammatory drug widely used in the clinic for its potent anti-inflammatory and analgesic properties, effectively inhibits the replication of <i>Alpha-</i>coronavirus HCoV-229E and <i>Beta-</i>coronavirus HCoV-OC43 in human lung-derived cells. Indomethacin does not interfere with HCoV binding or entry into target cells, but acts at late stages of the virus life cycle, inhibiting viral RNA synthesis and infectious viral particles production. Although INDO anti-inflammatory action is mediated by blocking cyclooxygenase-1 and -2 (COX-1/2) enzymatic activity, the antiviral effect appears to be cyclooxygenase-independent and is not mimicked by the potent COX-1/2 inhibitor aspirin. Interestingly we found that both seasonal HCoVs markedly (&gt;100 fold) induce the expression of the pro-inflammatory mediator COX-2 in lung cells; notably, INDO-treatment was found to effectively inhibit virus-induced COX-2 expression at the transcriptional level, revealing an additional mechanism to prevent COX-2-mediated inflammatory reactions in HCoV-infected lung cells, besides COX activity inhibition. Altogether the results indicate that indomethacin, possessing both potent anti-inflammatory properties and a direct antiviral activity against HCoV, could be effective in the treatment of <i>Alpha-</i> and <i>Beta-</i>coronavirus infections.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tramontozzi</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riccio</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pauciullo</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Frazia</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Translational Pharmacology, CNR, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santoro</LastName><ForeName>M Gabriella</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Translational Pharmacology, CNR, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Virus Erad</MedlineTA><NlmUniqueID>101654142</NlmUniqueID><ISSNLinking>2055-6640</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral</Keyword><Keyword MajorTopicYN="N">Cyclooxygenase-2</Keyword><Keyword MajorTopicYN="N">HCoV-229E</Keyword><Keyword MajorTopicYN="N">HCoV-OC43</Keyword><Keyword MajorTopicYN="N">eIF2α</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39399815</ArticleId><ArticleId IdType="pmc">PMC11470169</ArticleId><ArticleId IdType="doi">10.1016/j.jve.2024.100387</ArticleId><ArticleId IdType="pii">S2055-6640(24)00024-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cui J., Li F., Shi Z.L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–192. doi: 10.1038/s41579-018-0118-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0118-9</ArticleId><ArticleId IdType="pmc">PMC7097006</ArticleId><ArticleId IdType="pubmed">30531947</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung T.S., Liu D.X. Human coronavirus: host-pathogen interaction. Annu Rev Microbiol. 2019;73:529–557. doi: 10.1146/annurev-micro-020518-115759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-micro-020518-115759</ArticleId><ArticleId IdType="pubmed">31226023</ArticleId></ArticleIdList></Reference><Reference><Citation>V'kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19:155–170. doi: 10.1038/s41579-020-00468-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId><ArticleId IdType="pmc">PMC7592455</ArticleId><ArticleId IdType="pubmed">33116300</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov P.V., Ghafari M., Beer M., et al. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21:361–379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers M.M., Haagmans B.L. SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022;20:270–284. doi: 10.1038/s41579-022-00713-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00713-0</ArticleId><ArticleId IdType="pubmed">35354968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim Y.X., Ng Y.L., Tam J.P., Liu D. Human coronaviruses: a review of virus–host interactions. Diseases. 2016;4:26. doi: 10.3390/diseases4030026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases4030026</ArticleId><ArticleId IdType="pmc">PMC5456285</ArticleId><ArticleId IdType="pubmed">28933406</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D.X., Liang J.Q., Fung T.S. In: Encyclopedia of Virology. fourth ed. Bamford D., Zuckerman M., editors. Elsevier Ltd., Academic Press; 2021. Human coronavirus-229e, -OC43, -NL63, and -HKU1 (Coronaviridae) pp. 428–440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-809633-8.21501-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbour N., Day R., Newcombe J., Talbot P.J. Neuroinvasion by human respiratory coronaviruses. J Virol. 2000;74:8913–8921. doi: 10.1128/JVI.74.19.8913-8921.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.19.8913-8921.2000</ArticleId><ArticleId IdType="pmc">PMC102086</ArticleId><ArticleId IdType="pubmed">10982334</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu S.S., Hung Chan K., Wing Chu K., et al. Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin Infect Dis. 2005;40:1721–1729. doi: 10.1086/430301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/430301</ArticleId><ArticleId IdType="pmc">PMC7107956</ArticleId><ArticleId IdType="pubmed">15909257</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorse G.J., O'Connor T.Z., Hall S.L., Vitale J.N., Nichol K.L. Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease. J Infect Dis. 2009;199:847–857. doi: 10.1086/597122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/597122</ArticleId><ArticleId IdType="pmc">PMC7110218</ArticleId><ArticleId IdType="pubmed">19239338</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacomy H., Fragoso G., Almazan G., Mushynski W.E., Talbot P.J. Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice. Virology. 2006;349:335–346. doi: 10.1016/j.virol.2006.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2006.01.049</ArticleId><ArticleId IdType="pmc">PMC7111850</ArticleId><ArticleId IdType="pubmed">16527322</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfopoulou S., Brown J.R., Davies E.G., et al. Human coronavirus OC43 associated with fatal encephalitis. N Engl J Med. 2016;375:497–498. doi: 10.1056/NEJMc1509458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1509458</ArticleId><ArticleId IdType="pubmed">27518687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pene F., Merlat A., Vabret A., et al. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis. 2003;37:929–932. doi: 10.1086/377612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/377612</ArticleId><ArticleId IdType="pmc">PMC7107892</ArticleId><ArticleId IdType="pubmed">13130404</ArticleId></ArticleIdList></Reference><Reference><Citation>Risku M., Lappalainen S., Räsänen S., Vesikari T. Detection of human coronaviruses in children with acute gastroenteritis. J Clin Virol. 2010;48:27–30. doi: 10.1016/j.jcv.2010.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2010.02.013</ArticleId><ArticleId IdType="pmc">PMC7108425</ArticleId><ArticleId IdType="pubmed">20233673</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Liu W., Zhang S., et al. Two novel human coronavirus OC43 genotypes circulating in hospitalized children with pneumonia in China. Emerg Microb Infect. 2022;11:168–171. doi: 10.1080/22221751.2021.2019560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2019560</ArticleId><ArticleId IdType="pmc">PMC8741245</ArticleId><ArticleId IdType="pubmed">34907853</ArticleId></ArticleIdList></Reference><Reference><Citation>Esper F., Shapiro E.D., Weibel C., Ferguson D., Landry M.L., Kahn J.S. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis. 2005;191:499–502. doi: 10.1086/428291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/428291</ArticleId><ArticleId IdType="pmc">PMC7199489</ArticleId><ArticleId IdType="pubmed">15655771</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirato K., Imada Y., Kawase M., Nakagaki K., Matsuyama S., Taguchi F. Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease. J Med Virol. 2014;86:2146–2153. doi: 10.1002/jmv.23950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23950</ArticleId><ArticleId IdType="pmc">PMC7166330</ArticleId><ArticleId IdType="pubmed">24760654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann C.C., Lane T.E., Stohlman S.A. Coronavirus infection of the central nervous system: host-virus stand-off. Nat Rev Microbiol. 2006;4:121–132. doi: 10.1038/nrmicro1343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1343</ArticleId><ArticleId IdType="pmc">PMC7096820</ArticleId><ArticleId IdType="pubmed">16415928</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Q., Yang Y., Gao J. Infectivity of human coronavirus in the brain. EBioMedicine. 2020;56 doi: 10.1016/j.ebiom.2020.102799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102799</ArticleId><ArticleId IdType="pmc">PMC7255711</ArticleId><ArticleId IdType="pubmed">32474399</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbour N., Côté G., Lachance C., Tardieu M., Cashman N.R., Talbot P.J. Acute and persistent infection of human neural cell lines by human coronavirus OC43. J Virol. 1999;73:3338–3350. doi: 10.1128/JVI.73.4.3338-3350.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.4.3338-3350.1999</ArticleId><ArticleId IdType="pmc">PMC104098</ArticleId><ArticleId IdType="pubmed">10074188</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbour N., Ekandé S., Côté G., et al. Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E. J Virol. 1999;73:3326–3337. doi: 10.1128/JVI.73.4.3326-3337.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.4.3326-3337.1999</ArticleId><ArticleId IdType="pmc">PMC104097</ArticleId><ArticleId IdType="pubmed">10074187</ArticleId></ArticleIdList></Reference><Reference><Citation>Edridge A.W.D., Kaczorowska J., Hoste A.C.R., et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020;26:1691–1693. doi: 10.1038/s41591-020-1083-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1083-1</ArticleId><ArticleId IdType="pubmed">32929268</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro M.G., Carafoli E. Remdesivir: from ebola to COVID-19. Biochem Biophys Res Commun. 2021;538:145–150. doi: 10.1016/j.bbrc.2020.11.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.11.043</ArticleId><ArticleId IdType="pmc">PMC7836944</ArticleId><ArticleId IdType="pubmed">33388129</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., et al. MOVe-OUT Study Group Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–520. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., et al. EPIC-HR Investigators Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397–1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Vane J.R., Botting R.M. Mechanism of action of antiinflammatory drugs. Int J Tissue React. 1998;20:3–15.</Citation><ArticleIdList><ArticleId IdType="pubmed">9561441</ArticleId></ArticleIdList></Reference><Reference><Citation>Blobaum A.L., Marnett L.J. Structural and functional basis of cyclooxygenase inhibition. J Med Chem. 2007;50:1425–1441. doi: 10.1021/jm0613166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm0613166</ArticleId><ArticleId IdType="pubmed">17341061</ArticleId></ArticleIdList></Reference><Reference><Citation>Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97–120. doi: 10.1146/annurev.pharmtox.38.1.97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.38.1.97</ArticleId><ArticleId IdType="pubmed">9597150</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouzer C.A., Marnett L.J. Cyclooxygenases: structural and functional insights. J Lipid Res. 2009;50:S29–S34. doi: 10.1194/jlr.R800042-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R800042-JLR200</ArticleId><ArticleId IdType="pmc">PMC2674713</ArticleId><ArticleId IdType="pubmed">18952571</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A., Coccia M., Trotta E., Angelini M., Santoro M.G. Regulation of cyclooxygenase-2 expression by heat: a novel aspect of heat shock factor 1 function in human cells. PLoS One. 2012;7 doi: 10.1371/journal.pone.0031304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031304</ArticleId><ArticleId IdType="pmc">PMC3275557</ArticleId><ArticleId IdType="pubmed">22347460</ArticleId></ArticleIdList></Reference><Reference><Citation>Inglot A.D. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J Gen Virol. 1969;4:203–214. doi: 10.1099/0022-1317-4-2-203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-4-2-203</ArticleId><ArticleId IdType="pubmed">4306296</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossen J.W., Bouma J., Raatgeep R.H., Büller H.A., Einerhand A.W. Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step. J Virol. 2004;78:9721–9730. doi: 10.1128/JVI.78.18.9721-9730.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.18.9721-9730.2004</ArticleId><ArticleId IdType="pmc">PMC514972</ArticleId><ArticleId IdType="pubmed">15331705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrami H., Daryani N.E., Haghpanah B., et al. Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial. Am J Gastroenterol. 2005;100:856–861. doi: 10.1111/j.1572-0241.2005.41144.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2005.41144.x</ArticleId><ArticleId IdType="pubmed">15784032</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H., Cong J.P., Yu D., Bresnahan W.A., Shenk T.E. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci USA. 2002;99:3932–3937. doi: 10.1073/pnas.052713799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.052713799</ArticleId><ArticleId IdType="pmc">PMC122626</ArticleId><ArticleId IdType="pubmed">11867761</ArticleId></ArticleIdList></Reference><Reference><Citation>Amici C., La Frazia S., Brunelli C., Balsamo M., Angelini M., Santoro M.G. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2α kinase PKR. Cell Microbiol. 2015;17:1391–1404. doi: 10.1111/cmi.12446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cmi.12446</ArticleId><ArticleId IdType="pmc">PMC7162271</ArticleId><ArticleId IdType="pubmed">25856684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez J., Alcami J., Arnaiz-Villena A., et al. Indomethacin in the relief of AIDS symptoms. Lancet. 1986;2:570. doi: 10.1016/s0140-6736(86)90132-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(86)90132-7</ArticleId><ArticleId IdType="pubmed">2875297</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourinbaiar A.S., Lee-Huang S. Potentiation of anti-HIV activity of anti-inflammatory drugs, dexamethasone and indomethacin, by MAP30, the antiviral agent from bitter melon. Biochem Biophys Res Commun. 1995;208:779–785. doi: 10.1006/bbrc.1995.1405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1995.1405</ArticleId><ArticleId IdType="pubmed">7695636</ArticleId></ArticleIdList></Reference><Reference><Citation>Amici C., Di Caro A., Ciucci A., et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther. 2006;11:1021–1030. doi: 10.1177/135965350601100803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135965350601100803</ArticleId><ArticleId IdType="pubmed">17302372</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel Shaheed C., Beardsley J., Day R.O., McLachlan A.J. Immunomodulatory effects of pharmaceutical opioids and antipyretic analgesics: mechanisms and relevance to infection. Br J Clin Pharmacol. 2022;88:3114–3131. doi: 10.1111/bcp.15281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15281</ArticleId><ArticleId IdType="pubmed">35229890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Li P., Xu L., et al. Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response. iScience. 2023;26 doi: 10.1016/j.isci.2023.107631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.107631</ArticleId><ArticleId IdType="pmc">PMC10474465</ArticleId><ArticleId IdType="pubmed">37664584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravichandran R., Mohan S.K., Sukumaran S.K., et al. An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients. Sci Rep. 2022;12 doi: 10.1038/s41598022103701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598022103701</ArticleId><ArticleId IdType="pmc">PMC9016692</ArticleId><ArticleId IdType="pubmed">35440611</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunelli C., Amici C., Angelini M., Fracassi C., Belardo G., Santoro M.G. The non-steroidal anti-inflammatory drug indomethacin activates the eIF2α kinase PKR, causing a translational block in human colorectal cancer cells. Biochem J. 2012;443:379–386. doi: 10.1042/BJ20111236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20111236</ArticleId><ArticleId IdType="pubmed">22268531</ArticleId></ArticleIdList></Reference><Reference><Citation>Riccio A., Santopolo S., Rossi A., Piacentini S., Rossignol J.F., Santoro M.G. Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence. Cell Mol Life Sci. 2022;79:227. doi: 10.1007/s00018-022-04246-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-022-04246-w</ArticleId><ArticleId IdType="pmc">PMC8989121</ArticleId><ArticleId IdType="pubmed">35391601</ArticleId></ArticleIdList></Reference><Reference><Citation>Piacentini S., La Frazia S., Riccio A., et al. Nitazoxanide inhibits paramyxovirus replication by targeting the fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57. Sci Rep. 2018;8 doi: 10.1038/s41598-018-28172-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-28172-9</ArticleId><ArticleId IdType="pmc">PMC6041319</ArticleId><ArticleId IdType="pubmed">29992955</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro M.G., Favalli C., Mastino A., Jaffe B.M., Esteban M., Garaci E. Antiviral activity of a synthetic analog of prostaglandin A in mice infected with influenza A virus. Arch Virol. 1988;99:89–100. doi: 10.1007/BF01311026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01311026</ArticleId><ArticleId IdType="pubmed">3355375</ArticleId></ArticleIdList></Reference><Reference><Citation>Minenkova O., Santapaola D., Milazzo F.M., et al. Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy. Mol Ther. 2022;30:1979–1993. doi: 10.1016/j.ymthe.2022.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.02.013</ArticleId><ArticleId IdType="pmc">PMC8837488</ArticleId><ArticleId IdType="pubmed">35167974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Jackson C.B., Mou H., et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020;11:6013. doi: 10.1038/s41467-020-19808-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19808-4</ArticleId><ArticleId IdType="pmc">PMC7693302</ArticleId><ArticleId IdType="pubmed">33243994</ArticleId></ArticleIdList></Reference><Reference><Citation>Campeau E., Ruhl V.E., Rodier F., et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One. 2009;4 doi: 10.1371/journal.pone.0006529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0006529</ArticleId><ArticleId IdType="pmc">PMC2717805</ArticleId><ArticleId IdType="pubmed">19657394</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro M.G., Jaffe B.M., Garaci E., Esteban M. Antiviral effect of prostaglandins of the A series: inhibition of Vaccinia virus replication in cultured cells. J Gen Virol. 1982;63:435–440. doi: 10.1099/0022-1317-63-2-435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-63-2-435</ArticleId><ArticleId IdType="pubmed">6185627</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro M.G., Amici C., Elia G., Benedetto A., Garaci E. Inhibition of virus protein glycosylation as the mechanism of the antiviral action of prostaglandin A in Sendai virus-infected cells. J Gen Virol. 1989;70:789–800. doi: 10.1099/0022-1317-70-4-789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-70-4-789</ArticleId><ArticleId IdType="pubmed">2543761</ArticleId></ArticleIdList></Reference><Reference><Citation>Coccia M., Rossi A., Riccio A., Trotta E., Santoro M.G. Human NF-κB repressing factor acts as a stress-regulated switch for ribosomal RNA processing and nucleolar homeostasis surveillance. Proc Natl Acad Sci USA. 2017;114:1045–1050. doi: 10.1073/pnas.1616112114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1616112114</ArticleId><ArticleId IdType="pmc">PMC5293105</ArticleId><ArticleId IdType="pubmed">28096332</ArticleId></ArticleIdList></Reference><Reference><Citation>Piacentini S., Riccio A., Santopolo S., et al. The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein. Front Microbiol. 2023;14 doi: 10.3389/fmicb.2023.1206951.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2023.1206951</ArticleId><ArticleId IdType="pmc">PMC10497118</ArticleId><ArticleId IdType="pubmed">37705731</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijgen L., Keyaerts E., Moës E., Maes P., Duson G., Van Ranst M. Development of one-step, real-time, quantitative reverse transcriptase PCR assays for absolute quantitation of human coronaviruses OC43 and 229E. J Clin Microbiol. 2005;43:5452–5456. doi: 10.1128/JCM.43.11.5452-5456.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.43.11.5452-5456.2005</ArticleId><ArticleId IdType="pmc">PMC1287813</ArticleId><ArticleId IdType="pubmed">16272469</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzwarth G., Bhandari A., Tommervik L., Macosko J.C., Ornelles D.A., Lyles D.S. Vesicular stomatitis virus nucleocapsids diffuse through cytoplasm by hopping from trap to trap in random directions. Sci Rep. 2020;10 doi: 10.1038/s41598-020-66942-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-66942-6</ArticleId><ArticleId IdType="pmc">PMC7326962</ArticleId><ArticleId IdType="pubmed">32606395</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo S.L., Wark P.A.B., Esneau C., Nichol K.S., Hsu A.C., Bartlett N.W. Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in differentiated primary human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2020;319:L926–L931. doi: 10.1152/ajplung.00374.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00374.2020</ArticleId><ArticleId IdType="pmc">PMC7758816</ArticleId><ArticleId IdType="pubmed">32903043</ArticleId></ArticleIdList></Reference><Reference><Citation>Karousis E.D., Schubert K., Ban N. Coronavirus takeover of host cell translation and intracellular antiviral response: a molecular perspective. EMBO J. 2024;43:151–167. doi: 10.1038/s44318-023-00019-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44318-023-00019-8</ArticleId><ArticleId IdType="pmc">PMC10897431</ArticleId><ArticleId IdType="pubmed">38200146</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolliver S.M., Galbraith C., Khaperskyy D.A. Human betacoronavirus OC43 interferes with the integrated stress response pathway in infected cells. Viruses. 2024;16:212. doi: 10.3390/v16020212.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16020212</ArticleId><ArticleId IdType="pmc">PMC10893100</ArticleId><ArticleId IdType="pubmed">38399988</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A., Khaperskyy D.A. Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit stress granule formation. PLoS Pathog. 2022;18 doi: 10.1371/journal.ppat.1011041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1011041</ArticleId><ArticleId IdType="pmc">PMC9810206</ArticleId><ArticleId IdType="pubmed">36534661</ArticleId></ArticleIdList></Reference><Reference><Citation>Krähling V., Stein D.A., Spiegel M., Weber F., Mühlberger E. Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity. J Virol. 2009;83:2298–2309. doi: 10.1128/JVI.01245-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01245-08</ArticleId><ArticleId IdType="pmc">PMC2643707</ArticleId><ArticleId IdType="pubmed">19109397</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan X., Hao Q., Mu Y., et al. Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein. Int J Biochem Cell Biol. 2006;38:1417–1428. doi: 10.1016/j.biocel.2006.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2006.02.003</ArticleId><ArticleId IdType="pmc">PMC7108415</ArticleId><ArticleId IdType="pubmed">16546436</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Yang Y., Gu C., et al. Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways. Faseb J. 2007;21:1586–1596. doi: 10.1096/fj.06-6589com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.06-6589com</ArticleId><ArticleId IdType="pubmed">17267381</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.S., Alfajaro M.M., Wei J., et al. bioRxiv; 2020. Cyclooxygenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication. [Preprint]</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.24.312769</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>